Research programme: cancer therapeutics - Alligator Bioscience

Drug Profile

Research programme: cancer therapeutics - Alligator Bioscience

Alternative Names: ADC-1001; ADC-1001-RA; ADC-1004; ADC-1004-CHIPS; ADC-1012; ADC-1014; ADC-1015; ADC-CHIPS; ATOR 1015; ATOR 1017; Bispecific antibodies for cancer indications - Alligator Bioscience; FIND-1001; FIND-1004; TNFR-SF + ND - bispecific antibody; TNFR-SF - monospecific antibody

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alligator Bioscience
  • Class Anti-inflammatories; Antihyperglycaemics; Antineoplastics; Antirheumatics; Bispecific antibodies; Proteins
  • Mechanism of Action CD137 antigen agonists; Complement C5a inhibitors; Cytotoxic T-lymphocyte antigen 4 modulators; Immunomodulators; Interleukin 1 receptor antagonists; Interleukin 23 inhibitors; OX40 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Inflammation

Highest Development Phases

  • Preclinical Solid tumours
  • Research Cancer
  • No development reported Diabetes mellitus; Gout; Inflammation; Juvenile rheumatoid arthritis; Rheumatoid arthritis
  • Discontinued Reperfusion injury

Most Recent Events

  • 13 Sep 2017 Alligator Bioscience, Center for Applied Medical Research (CIMA) and Clinica Universidad de Navarra entered into research agreement to further investigate ATOR 1017
  • 06 Sep 2017 Alligator Bioscience plans to initiate clinical development of ATOR 1015 in 2018
  • 08 Jul 2016 Preclinical development of ADC 1015 is ongoing in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top